Literature DB >> 11179055

Gadolinium prevents stretch-mediated contractile dysfunction in isolated papillary muscles.

A C Nicolosi1, C S Kwok, S J Contney, G N Olinger, Z J Bosnjak.   

Abstract

We tested the hypothesis that overstretching the myocardium could induce and/or exacerbate contractile dysfunction via stretch-activated (SA) ion channels. Maximum developed tension (T(max)), normalized to a control value, was compared in guinea pig papillary muscles held at one of three resting lengths (physiological stretch, overstretch, and unloaded) for 85 min. Overstretched muscles exhibited decreased contractile force (T(max) = 0.77 +/- 0.03) compared with physiological and unloaded muscles (T(max) = 0.93 +/- 0.05 and 1.03 +/- 0.07, respectively). Gd(3+), an SA channel antagonist, eliminated the adverse effect of overstretching (T(max) = 0.98 +/- 0.06), but nifedipine, a dihydropyridine (DHP) antagonist of L-type calcium channels, did not (T(max) = 0.82 +/- 0.04). Exposure to modified hypoxia-reoxygenation (MHR) during physiological stretch resulted in decreased contractility (T(max) = 0.63 +/- 0.07), an effect that was exacerbated by overstretching (T(max) = 0.44 +/- 0.04). Gd(3+) mitigated the effects of overstretch during MHR (T(max) = 0.64 +/- 0.05), but DHP did not (T(max) = 0.48 +/- 0.04). These data suggest that overstretching of the myocardium contributes to contractile abnormalities via SA channels that are distinct from L-type calcium channels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179055     DOI: 10.1152/ajpheart.2001.280.3.H1122

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  1 in total

1.  Gadolinium limits myocardial infarction in the rat: dose-response, temporal relations and mechanisms.

Authors:  Alfred C Nicolosi; Jennifer L Strande; Anna Hsu; Xiangping Fu; Jidong Su; Garrett J Gross; John E Baker
Journal:  J Mol Cell Cardiol       Date:  2007-11-19       Impact factor: 5.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.